METABOLIC
Semaglutide
Explore compounded semaglutide injections for weight management, with clinical review, medication, shipping and ongoing care in one monthly plan.
From $129/mo
ODT (oral dissolving)
Semaglutide ODT
A compounded semaglutide and ondansetron dissolving tablet, with formulation-specific clinical review, pharmacy fulfillment and follow-up.
Your treatment plan
From $209/month equivalent
$627 billed every 3 months3-month commitment$229 billed monthly also availableAll fees includedView plan details
- Licensed clinicians
- Compounded by a licensed 503A pharmacy
- No clinic visit
Alternate dosage forms are compounded only where a licensed clinician documents a patient-specific clinical need that a commercially available product cannot meet. They are not interchangeable with, and are not substitutes for, FDA-approved products. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.
Questions before you start?
Compare this treatmentWhat will I pay?
Standard plan price$209 per month equivalent, billed $627 every 3 months. 3-month commitment.
Billing options and renewal
The standard Semaglutide ODT price is $229 billed monthly, or $627 paid up front every three months ($209 per month equivalent; a three-month commitment). These are recurring prices before any eligible first-order discount. A first-order offer reduces that order only; renewal uses the standard price for the chosen plan. A monthly equivalent is not a monthly charge.
What should I know about this treatment?
A compounded semaglutide and ondansetron dissolving tablet, with formulation-specific clinical review, pharmacy fulfillment and follow-up.
Read the evidence and its limitationsWhat should I review before starting?
Boxed warning
FDA-approved semaglutide products carry a boxed warning concerning thyroid C-cell tumors observed in rodents, which is why a personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication, and why pancreatitis history, pregnancy plans, and significant gastrointestinal disease are screened before prescribing.
A licensed clinician reviews your health history and medications and determines whether treatment is appropriate for you.
Read the full Important Safety InformationHow do I request Semaglutide ODT online?
Complete the online assessment with your health history, current medications and treatment goals. A licensed clinician reviews the information and decides whether to prescribe. If prescribed, a licensed pharmacy prepares and ships your medication.
See how care worksWhat It Is
Understand the tablet before you choose a path.
This compounded orally disintegrating tablet combines semaglutide with ondansetron. An ODT is designed to dissolve in the mouth. It is a distinct preparation with its own prescribing considerations.
Your clinician reviews your medical needs, other medicines and the available options before deciding whether this formulation belongs in your care. A preference for tablets alone does not establish a medical reason for compounding.
Studies of approved injections do not establish the absorption, safety or effectiveness of this compounded tablet. It is also different from FDA-approved swallowed semaglutide tablets.
Your prescription supplies the dose and use instructions. Clinical review, prescribed medication, pharmacy fulfillment, shipping and care-team messaging are included in the plan.
Read the evidenceWho It's For
Bring your practical questions into the visit.
01
Questions about injections
If needles, handling or storage concern you, discuss them with your clinician alongside the evidence for the available oral and injectable options.
02
Previous treatment experience
Share the products you have tried, your response and any side effects. That history helps your clinician assess the next step.
03
A routine you can follow
Talk through your day-to-day needs and ask how a prescribed formulation would fit. Clinical suitability comes before choosing a format.
This compounded formulation is not FDA-approved. A clinician evaluates the available treatments and whether an individual medical need supports this preparation. Your formulation and dose are prescribed after review.
This might not be the right fit if:
- Personal or family history of medullary thyroid carcinoma or MEN 2
- History of pancreatitis
- Pregnancy, planned pregnancy, or breastfeeding
- Severe gastrointestinal disease, including gastroparesis
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Your Plan
Semaglutide ODT, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- Format
- ODT (oral dissolving)
- Strength
- Semaglutide 4 mg, 6 mg or 12 mg with ondansetron 2 mg
- Total plan quantity
- 90 tablets
- Billed amount
- $627 every 3 months
- Monthly equivalent
- $209 per month
- Commitment
- 3 months
- Monthly option
- $229 billed monthly · 30 tablets total plan quantity
- Fees
- Included in the plan price
Strength describes the preparation. Total plan quantity is the amount included in that plan, not your dose or dosing schedule. Follow the directions on your prescription.
Compounded by a licensed 503A pharmacy
Semaglutide ODT
ODT (oral dissolving)
From $209
Monthly equivalent. All fees included.
$627 billed every 3 months. 3-month commitment.
- Clinician review of why an alternate route may be appropriate
- Compounded orally disintegrating semaglutide prepared to the individual prescription
- Route-specific prescribing and adjustment rather than injection-dose substitution
- Follow-up tied to response, tolerability, and the broader metabolic plan
$209 /mo equivalent · 3-month commitment
$209/mo equivalent, all-in. Consultation is included in the plan price, not added on top. Consultation, cancellation and refund policy.
What happens when I start?
You'll begin an online assessment for Semaglutide ODT.
- Tell your clinician about you. Share your goals, health history and current medications.
- Review your plan. Confirm the treatment option, billing interval and total shown in the assessment.
- Get an individual clinical review. Your clinician decides whether to prescribe. If prescribed, a licensed pharmacy fulfills your prescription.
Starting an assessment doesn't guarantee a prescription. How care works
Alternate dosage forms are compounded only where a licensed clinician documents a patient-specific clinical need that a commercially available product cannot meet. They are not interchangeable with, and are not substitutes for, FDA-approved products. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.
*Price reflects a 3-month commitment. See billing details above.
Your subscription renews at your selected billing interval. Cancel through your member dashboard before the next billing date to stop future charges. Cancellation does not refund the current billing period. See cancellation and refund terms.
Have a question about this plan?
Clinical questions
Message your provider about dosing, side effects, your response or changes in your health.
Open patient portalNew to AnthologyRX? Ask our team about getting started.
Care and cost
Clear pricing. Care that follows through.
Your plan brings the clinical review, prescribed medication, pharmacy fulfillment, shipping and care-team messaging together. The consultation is included in your plan price.
- What will I pay at the start and on renewal?
- $229 billed monthly, or $627 paid up front every three months ($209/month equivalent; three-month commitment). These are the standard recurring prices, before any eligible first-order discount. The monthly equivalent is not a monthly charge.
- Does a dose change affect the price?
- The displayed price is for the Semaglutide ODT plan and selected billing interval. Confirm the prescribed strength, quantity and price before starting or changing treatment. Moving to a different product or formulation can change the cost. Your clinician decides whether a dose change is appropriate.
- How is this formulation different?
- The current dissolving tablet combines semaglutide with ondansetron. It is a different formulation from an injection or an approved swallowed tablet; their study results do not establish the results of this ODT. Explore our other semaglutide preparations: Semaglutide injections or Lower-dose injections with B12. Each requires its own clinical evaluation.
- Who helps when I have a question?
- Use the patient portal for questions about dosing, side effects or changes in your health. AnthologyRX support can help with billing, shipping and portal access.
The people behind your care
Guidance from the first question onward.
Independent clinical care
Licensed clinicians affiliated with Arora Health & Aesthetics, LLC review your health history, medications and goals, then discuss whether Semaglutide ODT or another approach fits your needs.
Medical information on this page reviewed by Dr. Dylan Russell, MD, Chief Health Officer on . Your prescribing clinician provides your individual care.
Verify Dr. Russell's medical licensePharmacy quality that matters
Prepared to your prescription by a licensed compounding pharmacy. Our partners have verified quality programs covering identity, potency, independent testing and batch documentation.
Compounded preparations are not FDA-approved. Pharmacy quality controls and your clinician's evaluation of treatment evidence each have a role in your care.
Pharmacy & fulfillment
Listed dispensing pharmacy
- The Pharmacy Hub LLCFormulation: Semaglutide ODTVerify: Florida pharmacy license PH33959
Availability depends on your prescription and location. For pharmacy questions, contact our team.
A direct line for follow-up
Message your provider through the patient portal about dosing, side effects, your response or changes in your health. Contact AnthologyRX support for billing, shipment or portal-access help.
The Evidence
What the research shows
GLP-1 is a gut hormone released after meals and inactivated extremely rapidly.
30 amino acids
length of the native peptide hormone
The detail
Glucagon-like peptide-1 is a 30-amino-acid peptide hormone produced in intestinal epithelial endocrine L-cells by differential processing of proglucagon, released in response to meal intake, and inactivated extremely rapidly by the enzyme dipeptidyl peptidase-4.1
GLP-1 triggers glucose-dependent insulin release, slows gastric emptying and promotes satiety.
The detail
As an incretin it is secreted within minutes of nutrient ingestion, and incretin-receptor activation on pancreatic islet beta-cells leads to glucose-dependent insulin secretion, while glucagon-like peptide-1 additionally exerts glucoregulatory action through slowing of gastric emptying and glucose-dependent inhibition of glucagon secretion and promotes satiety.2
Semaglutide binds the same receptor as the natural hormone it closely resembles.
The same receptor
semaglutide selectively binds and activates the GLP-1 receptor, the target for the native hormone
The detail
Semaglutide is a GLP-1 analogue with 94 percent sequence homology to human GLP-1 that selectively binds to and activates the GLP-1 receptor, the target for the native hormone, and FDA labeling describes the resulting glucose-lowering mechanism as stimulation of insulin secretion and lowering of glucagon secretion, both in a glucose-dependent manner, together with a minor delay in gastric emptying in the early postprandial phase.3
Labeling describes GLP-1 as an appetite regulator, with animal data showing brain activity.
The detail
FDA labeling further describes glucagon-like peptide-1 as a physiological regulator of appetite and caloric intake, states that the GLP-1 receptor is present in several areas of the brain involved in appetite regulation, and reports that animal studies show semaglutide distributed to and activated neurons in brain regions involved in regulation of food intake.4
Approved semaglutide injections have a half-life of about one week.
99 percent
bound to plasma albumin, the principal mechanism of protraction
The detail
The pharmacokinetic basis for once-weekly subcutaneous administration is described in the same labeling as albumin binding, identified as the principal mechanism of protraction because it decreases renal clearance and protects against metabolic degradation, with semaglutide extensively bound to plasma albumin at greater than 99 percent, an elimination half-life of approximately one week, and steady-state exposure reached after four to five weekly doses.5
What it does not show
FDA does not verify the safety, effectiveness or quality of compounded drugs.
The detail
A compounded preparation is not an FDA-approved drug product: FDA states that compounded drugs are not FDA-approved and that the agency does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.7
Everything above is mechanism from labeling, not trial results.
The detail
A pathway is not an outcome. Everything above is drawn from the clinical pharmacology section of FDA labeling, which describes how the molecule acts. This block deliberately stops there rather than reproducing the separate clinical studies section in which trial results for FDA-approved finished drug products are reported, because a described pathway is not a measured outcome.3
No orally disintegrating semaglutide formulation is characterized in FDA labeling.
0.4 to 2 percent
oral bioavailability of the SNAC tablet, the only oral form characterized
The detail
FDA labeling characterizes orally administered semaglutide only in tablet formulations co-formulated with the absorption enhancer SNAC, with absorption occurring predominantly in the stomach and absolute oral bioavailability of approximately 0.4 to 2 percent, and no orally disintegrating or oromucosal semaglutide formulation is characterized in FDA labeling.6
Exposure, onset and duration have not been characterized for this compounded preparation.
FDA says compounding is for patients an approved drug cannot serve.
The detail
FDA advises that compounded drugs should be used only in patients whose medical needs cannot be met by an FDA-approved drug, and identifies a claim that a compounded drug is the same as an FDA-approved drug as a warning sign for consumers.8
- Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007.
- Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007.
- FDA-approved semaglutide injection prescribing information, section…DailyMed
- FDA-approved semaglutide prescribing information, section 12.1…DailyMed
- FDA-approved semaglutide injection prescribing information, section…DailyMed
- FDA, Compounding and the FDA: Questions and Answers.FDA
- FDA-approved oral semaglutide tablet prescribing information, section…DailyMed
- FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.FDA
Important Safety Information
Boxed warning
FDA-approved semaglutide products carry a boxed warning concerning thyroid C-cell tumors observed in rodents, which is why a personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication, and why pancreatitis history, pregnancy plans, and significant gastrointestinal disease are screened before prescribing.
Do not use if you have
- A personal or family history of medullary thyroid carcinoma or MEN 2
- Use of apomorphine or a known allergy to ondansetron
Serious risks
- Pancreatitis
- Gallbladder disease
- Acute kidney injury following the fluid loss that severe vomiting or diarrhea can cause
Commonly reported
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
The effects patients report most often are gastrointestinal, usually while a dose is being established. Those serious risks are described for FDA-approved finished drug products. This compounded orally disintegrating preparation has no safety database of its own, which is one more reason your clinician weighs the whole picture against your history before deciding whether the alternate route belongs in your plan. The tablet also contains ondansetron, so your clinician should review heart-rhythm risks and interactions with serotonergic medicines. Approved ondansetron labeling warns about QT prolongation and serotonin syndrome. 9
- DailyMed: Ondansetron prescribing information, contraindications and…DailyMed
Questions
Asked and answered.
Explore
More in Metabolic.
METABOLIC
Tirzepatide
Explore compounded tirzepatide injections for weight management, with clinical review, medication, shipping and ongoing care in one monthly plan.
From $169/mo
METABOLIC
Semaglutide + B12 Microdose
A lower-dose compounded semaglutide and vitamin B12 injection, with individual prescribing, pharmacy fulfillment and follow-up.
From $109/mo
